Tennant S N, Dixon J, Venable T C, Page H L, Roach A, Kaiser A B, Frederiksen R, Tacogue L, Kaplan P, Babu N S
Circulation. 1984 Apr;69(4):756-60. doi: 10.1161/01.cir.69.4.756.
The efficacy of intracoronary urokinase and streptokinase were compared in 80 patients with acute myocardial infarction in a prospective, randomized, double-blind study. Urokinase was infused into the occluded coronary artery at 6000 U/min, and streptokinase was infused at 2000 U/min. Maximal duration of infusion was 2 hr. The frequency of successfully opening the artery was similar for patients receiving urokinase (27 of 45, 60%) and those receiving streptokinase (20 of 35, 57%). Fibrinogen levels after infusion were measured in 63 patients. Nineteen of 29 streptokinase recipients had fibrinogen levels less than 100 mg/dl compared with levels of two of 34 urokinase recipients (p less than .001). Five of 45 (11%) patients receiving urokinase and 10 of 35 receiving streptokinase (29%) had bleeding complications (p less than .05). Major bleeding after early coronary artery bypass surgery was more frequent in the streptokinase group (four of five compared with a similar group of patients receiving urokinase (none of five). This study demonstrates that while urokinase and streptokinase have equal intracoronary thrombolytic efficacy, patients receiving urokinase have less systemic fibrinolysis and less perioperative bleeding with early surgery than do patients receiving streptokinase.
在一项前瞻性、随机、双盲研究中,对80例急性心肌梗死患者比较了冠状动脉内注射尿激酶和链激酶的疗效。尿激酶以6000 U/分钟的速度注入闭塞的冠状动脉,链激酶以2000 U/分钟的速度注入。最大输注时间为2小时。接受尿激酶治疗的患者(45例中的27例,60%)和接受链激酶治疗的患者(35例中的20例,57%)成功开通动脉的频率相似。对63例患者输注后的纤维蛋白原水平进行了测量。29例接受链激酶治疗的患者中有19例纤维蛋白原水平低于100 mg/dl,而34例接受尿激酶治疗的患者中只有2例(p<0.001)。45例接受尿激酶治疗的患者中有5例(11%)出现出血并发症,35例接受链激酶治疗的患者中有10例(29%)出现出血并发症(p<0.05)。在冠状动脉搭桥手术早期,链激酶组严重出血更为常见(5例中有4例,而接受尿激酶治疗的类似患者组中5例均无出血)。本研究表明,虽然尿激酶和链激酶具有同等的冠状动脉内溶栓疗效,但与接受链激酶治疗的患者相比,接受尿激酶治疗的患者全身纤溶作用较小,早期手术围手术期出血较少。